February 2008 Summary Available

Posted by arubenstein as 1. Monthly Reports

The OnBioVC February 2008 monthly summary is now available on the REPORTS tab (here) if reading via email or RSS reader or if on the site simply click on the tab above. Thank you.

Be the first to comment...

Taligen Therapeutics, Inc.: Series B $65M

Posted by arubenstein as I - Series B, Q - 1Q08, R - ROCKY MOUNTAIN, X - AMD, X - Asthma, X - Inflammation

Taligen Therapeutics (Aurora, CO) a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease closed a $65M Series B financing. Participants include Alta Partners, Clarus Ventures, Sanderling Ventures, Tango and High Country Venture.

Be the first to comment...

Arriva Pharmaceuticals, Inc.: Series ? $6M

Posted by arubenstein as Q - 1Q08, R - WEST, X - Inflammation, X - Respiratory

Arriva Pharmaceuticals (Alameda, CA) a development stage biotechnology company focused anti-inflammatory therapies for treating respiratory diseases closed a $6M financing. Participants included Nordic Biotech and MPM Capital.

Be the first to comment...

TyRx Pharma, Inc.: Series A $25M

Posted by arubenstein as I - Series A, Q - 1Q08, R - NORTH EAST, X - Drug:Device Combo

TyRx Pharma (Monmouth Junction, NJ) a commercialization-stage developer of implantable drug-device combination products closed a $25M Series A financing. Participants include Clarus Ventures and Pappas Ventures.

Be the first to comment...

PhaseRx, Inc.: Series A $19M

Posted by arubenstein as I - Series A, Q - 1Q08, R - NORTH WEST, X - siRNA

PhaseRx (Seattle, WA) an early-stage siRNA therapeutic company closed a $19M Series A financing. Participants include 5AM Ventures, Arch Venture Partners and Versant Ventures.

Be the first to comment...

Cianna Medical, Inc.: Series A $9M

Posted by arubenstein as I - Series A, Q - 1Q08, R - WEST, X - Oncology

Cianna Medica (Aliso Viejo, CA) a brachytherapy medical device company focused on women’s health and dedicated to the innovative treatment of early-stage breast cancer closed a $9M Series A financing. Participants include BioLucent, Fog City Fund and Windamere Venture Partners.

Be the first to comment...

Obalon Therapeutics, Inc.: Series A $7.7M

Posted by arubenstein as I - Series A, Q - 1Q08, R - WEST, XX - Stealth Mode

Obalon Therapeutics (San Diego, CA) a stealth mode drug startup closed on a $4.7M tranche of a $7.7M Series A financing. Participants include Domain Associates, Okapi Ventures and Phagia Technology Inc.

Be the first to comment...

Adnavance Technologies, Inc.: Series B $3.6M

Posted by arubenstein as I - Series B, Q - 1Q08, R - INTERNATIONAL, X - Diagnostic, X - MRSA

Adnavance (Canada) developer of DNA detection molecular diagnostic tests for MRSA identification closed a $3.7M Series B financing. Participants include GrowthWorks Capital, JovInvestment Management and Business Development Bank of Canada.

Be the first to comment...

Vaccinex, Inc.: Series B $25M

Posted by arubenstein as I - Series B, Q - 1Q08, R - NORTH EAST, X - Antibody, X - Inflammation, X - Oncology

Vaccinex (Rochester, NY) a research and development stage antibody platform company focused on oncology and inflammation closed a $25M Series B financing. Participants include Teva Pharmaceuticals, Pan Atlantic Bank & Trust, Biocon and Toronto Investment Group.

Be the first to comment...

Affomix, Corp.: Series A $7M

Posted by arubenstein as I - Series A, Q - 1Q08, R - NORTH EAST, X - Antibody, X - Microarray

Affomic (New Haven, CT) a development stage biotechnology company designing antibody microarrays closed a $7M Series A financing. Participants include Connecticut Innovations, Elm Street Ventures, and Four Seasons Ventures.